Below are the most recent publications written about "Allopurinol" by people in Profiles.
-
Preston WA, Pace DJ, Altshuler PJ, Yi M, Kittle HD, Vincent SA, Andreoni KA, Frank AM, Glorioso JM, Ramirez CG, Maley WR, Shah AP, Bodzin AS. A propensity score matched analysis of liver transplantation outcomes in the setting of preservation solution shortage. Am J Transplant. 2024 Apr; 24(4):619-630.
-
Abhishek A, Cipolletta E, Nakafero G, Avery AJ, Mamas M, Tata LJ. Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink. Ann Rheum Dis. 2022 12; 81(12):1768-1769.
-
Battula NR, Andreoni KA. Oxygenated Preservation Solutions for Organ Preservation. Transplantation. 2019 02; 103(2):233-234.
-
Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19; 131(20):1763-71.
-
Jutkowitz E, Choi HK, Pizzi LT, Kuntz KM. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med. 2014 Nov 04; 161(9):617-26.
-
DuPont JJ, Ramick MG, Farquhar WB, Townsend RR, Edwards DG. NADPH oxidase-derived reactive oxygen species contribute to impaired cutaneous microvascular function in chronic kidney disease. Am J Physiol Renal Physiol. 2014 Jun 15; 306(12):F1499-506.
-
Burke PA, Malebranche L, Gakhal M, Rahman E, Saltzberg M. Sustained improvement of cardiac function with immunosuppressive therapy in a case of acute lymphocytic myocarditis secondary to allopurinol induced Stevens-Johnson syndrome. Del Med J. 2012 Dec; 84(12):381-3.
-
Meltzer M, Pizzi LT, Jutkowitz E. Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout. Evid Based Med. 2012 Aug; 17(4):105-8.
-
Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bola?os-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. 2010 Jul; 34(7):877-82.
-
Mosler P, Sherman S, Marks J, Watkins JL, Geenen JE, Jamidar P, Fogel EL, Lazzell-Pannell L, Temkit M, Tarnasky P, Block KP, Frakes JT, Aziz AA, Malik P, Nickl N, Slivka A, Goff J, Lehman GA. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc. 2005 Aug; 62(2):245-50.